These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 34868082)

  • 1. Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats.
    Tcheou J; Raskin A; Singh G; Kawabata H; Bielak D; Sun W; González-Domínguez I; Sather DN; García-Sastre A; Palese P; Krammer F; Carreño JM
    Front Immunol; 2021; 12():791764. PubMed ID: 34868082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice.
    Slamanig S; González-Domínguez I; Chang LA; Lemus N; Lai TY; Martínez JL; Singh G; Dolange V; Abdeljawad A; Kowdle S; Noureddine M; Warang P; Singh G; Lee B; García-Sastre A; Krammer F; Schotsaert M; Palese P; Sun W
    EBioMedicine; 2024 Jul; 105():105185. PubMed ID: 38848648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam.
    Duc Dang A; Dinh Vu T; Hai Vu H; Thanh Ta V; Thi Van Pham A; Thi Ngoc Dang M; Van Le B; Huu Duong T; Van Nguyen D; Lawpoolsri S; Chinwangso P; McLellan JS; Hsieh CL; Garcia-Sastre A; Palese P; Sun W; Martinez JL; Gonzalez-Dominguez I; Slamanig S; Manuel Carreño J; Tcheou J; Krammer F; Raskin A; Minh Vu H; Cong Tran T; Mai Nguyen H; Mercer LD; Raghunandan R; Lal M; White JA; Hjorth R; Innis BL; Scharf R
    Vaccine; 2022 Jun; 40(26):3621-3632. PubMed ID: 35577631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice.
    González-Domínguez I; Martínez JL; Slamanig S; Lemus N; Liu Y; Lai TY; Carreño JM; Singh G; Singh G; Schotsaert M; Mena I; McCroskery S; Coughlan L; Krammer F; García-Sastre A; Palese P; Sun W
    Microbiol Spectr; 2022 Jun; 10(3):e0153822. PubMed ID: 35658571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Newcastle Disease Virus (NDV)-based vaccine candidate against SARS-CoV-2 Omicron by intranasal immunization.
    Zhang QY; Zhang HQ; Zhang YN; Zhang ZR; Li XD; Hao MC; Zhang Y; Li JQ; Hu YY; Chen XL; Wang J; Shi YJ; Deng CL; Chen JJ; Ye HQ; Zhang B
    Antiviral Res; 2023 Dec; 220():105757. PubMed ID: 37984567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate.
    Sun W; Leist SR; McCroskery S; Liu Y; Slamanig S; Oliva J; Amanat F; Schäfer A; Dinnon KH; García-Sastre A; Krammer F; Baric RS; Palese P
    EBioMedicine; 2020 Dec; 62():103132. PubMed ID: 33232870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection.
    van der Ley PA; Zariri A; van Riet E; Oosterhoff D; Kruiswijk CP
    Front Immunol; 2021; 12():781280. PubMed ID: 34987509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses.
    Sun W; Liu Y; Amanat F; González-Domínguez I; McCroskery S; Slamanig S; Coughlan L; Rosado V; Lemus N; Jangra S; Rathnasinghe R; Schotsaert M; Martinez JL; Sano K; Mena I; Innis BL; Wirachwong P; Thai DH; Oliveira RDN; Scharf R; Hjorth R; Raghunandan R; Krammer F; García-Sastre A; Palese P
    Nat Commun; 2021 Oct; 12(1):6197. PubMed ID: 34707161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs.
    Lara-Puente JH; Carreño JM; Sun W; Suárez-Martínez A; Ramírez-Martínez L; Quezada-Monroy F; Paz-De la Rosa G; Vigueras-Moreno R; Singh G; Rojas-Martínez O; Chagoya-Cortés HE; Sarfati-Mizrahi D; Soto-Priante E; López-Macías C; Krammer F; Castro-Peralta F; Palese P; García-Sastre A; Lozano-Dubernard B
    mBio; 2021 Oct; 12(5):e0190821. PubMed ID: 34544278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction and immunogenicity of SARS-CoV-2 virus-like particle expressed by recombinant baculovirus BacMam.
    Nguyen HT; Falzarano D; Gerdts V; Liu Q
    Microbiol Spectr; 2024 Aug; 12(8):e0095924. PubMed ID: 38916311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A SARS-CoV-2 recombinant spike protein vaccine (S-268019-b) for COVID-19 prevention during the Omicron-dominant period: A phase 3, randomised, placebo-controlled clinical trial.
    Dinh Thiem V; Van Anh PT; Van Men C; Hung DT; Pollard AJ; Kamitani A; Tada Y; Fukuyama H; Iwasaki Y; Ariyasu M; Sonoyama T
    Vaccine; 2024 Jun; 42(17):3699-3709. PubMed ID: 38734495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal administration of unadjuvanted SARS-CoV-2 spike antigen boosts antigen-specific immune responses induced by parenteral protein subunit vaccine prime in mice and hamsters.
    Agbayani G; Akache B; Renner TM; Tran A; Stuible M; Dudani R; Harrison BA; Duque D; Bavananthasivam J; Deschatelets L; Hemraz UD; Régnier S; Durocher Y; McCluskie MJ
    Eur J Immunol; 2024 Jun; 54(6):e2350620. PubMed ID: 38561974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: protection of African green monkeys from COVID-19 disease.
    Nambulli S; Escriou N; Rennick LJ; Demers MJ; Tilston-Lunel NL; McElroy AK; Barbeau DJ; Crossland NA; Hoehl RM; Schrauf S; White AG; Borish HJ; Tomko JA; Frye LJ; Scanga CA; Flynn JL; Martin A; Gerke C; Hartman AL; Duprex WP
    J Virol; 2024 May; 98(5):e0176223. PubMed ID: 38563762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people.
    Narowski TM; Raphel K; Adams LE; Huang J; Vielot NA; Jadi R; de Silva AM; Baric RS; Lafleur JE; Premkumar L
    Cell Rep; 2022 Feb; 38(5):110336. PubMed ID: 35090596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal administration of a live-attenuated recombinant newcastle disease virus expressing the SARS-CoV-2 Spike protein induces high neutralizing antibody levels and protects from experimental challenge infection in hamsters.
    de Swart RL; de Leeuw OS; Oreshkova N; Gerhards NM; Albulescu IC; Vreman S; Gonzales JL; Maas R; van Kuppeveld FJM; Soema P; Bosch BJ; Peeters BPH
    Vaccine; 2022 Aug; 40(33):4676-4681. PubMed ID: 35820941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BNT162b vaccines protect rhesus macaques from SARS-CoV-2.
    Vogel AB; Kanevsky I; Che Y; Swanson KA; Muik A; Vormehr M; Kranz LM; Walzer KC; Hein S; Güler A; Loschko J; Maddur MS; Ota-Setlik A; Tompkins K; Cole J; Lui BG; Ziegenhals T; Plaschke A; Eisel D; Dany SC; Fesser S; Erbar S; Bates F; Schneider D; Jesionek B; Sänger B; Wallisch AK; Feuchter Y; Junginger H; Krumm SA; Heinen AP; Adams-Quack P; Schlereth J; Schille S; Kröner C; de la Caridad Güimil Garcia R; Hiller T; Fischer L; Sellers RS; Choudhary S; Gonzalez O; Vascotto F; Gutman MR; Fontenot JA; Hall-Ursone S; Brasky K; Griffor MC; Han S; Su AAH; Lees JA; Nedoma NL; Mashalidis EH; Sahasrabudhe PV; Tan CY; Pavliakova D; Singh G; Fontes-Garfias C; Pride M; Scully IL; Ciolino T; Obregon J; Gazi M; Carrion R; Alfson KJ; Kalina WV; Kaushal D; Shi PY; Klamp T; Rosenbaum C; Kuhn AN; Türeci Ö; Dormitzer PR; Jansen KU; Sahin U
    Nature; 2021 Apr; 592(7853):283-289. PubMed ID: 33524990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of intranasal vaccine based on SARS-CoV-2 spike protein during primary and booster immunizations in mice.
    Yang H; Xie Y; Li S; Bao C; Wang J; Li C; Nie J; Quan Y
    Hum Vaccin Immunother; 2024 Dec; 20(1):2364519. PubMed ID: 38880868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single intranasal dose of a live-attenuated parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in hamsters.
    Liu X; Luongo C; Matsuoka Y; Park HS; Santos C; Yang L; Moore IN; Afroz S; Johnson RF; Lafont BAP; Martens C; Best SM; Munster VJ; Hollý J; Yewdell JW; Le Nouën C; Munir S; Buchholz UJ
    Proc Natl Acad Sci U S A; 2021 Dec; 118(50):. PubMed ID: 34876520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical Trial.
    Bennett C; Rivers EJ; Woo W; Bloch M; Cheung K; Griffin P; Mohan R; Deshmukh S; Arya M; Cumming O; Neville AM; Pardey TM; Plested JS; Cloney-Clark S; Zhu M; Kalkeri R; Patel N; Buchanan A; Marcheschi A; Swan J; Smith G; Cho I; Glenn GM; Walker R; Mallory RM
    J Infect Dis; 2024 Jul; 230(1):e4-e16. PubMed ID: 39052718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.